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Abstract Strong evidence supports the ability of the
aldosterone/mineralocorticoid receptor (MR) system to
dominate long-term blood pressure control. It is also
increasingly recognized as an important mediator of
cardiovascular and renal diseases, particularly in the
presence of excessive salt intake. In a subgroup of
individuals with metabolic syndrome, adipocyte-derived
aldosterone-releasing factors cause inappropriate secretion
of aldosterone in the adrenal glands during salt loading,
resulting in the development of salt-induced hypertension
and cardiac and renal damage. On the other hand, emerging
data reveal that aldosterone is not a sole regulator of MR
activity. We have identified the signaling crosstalk between
MR and small GTPase Rac1 as a novel pathway to facilitate
MR signaling. Such a local control system for MR can also
be relevant to the pathogenesis of salt-sensitive hyperten-
sion, and future studies will clarify the detailed mechanism
for the intricate regulation of the aldosterone/MR cascade.
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Introduction
Although the precise mechanism of hypertension remains
unknown, there is ample evidence suggesting the central
role of the kidneys in long-term blood pressure control. The
cross-transplantation experiments in 1970s using a heredi-
tary model of hypertension afforded strong evidence for the
role of kidneys in blood pressure elevation [1]. The primacy
of renal salt handling was further strengthened by the
concept of pressure natriuresis [2], whereby the kidneys
alter sodium and water excretion in response to changes in
arterial pressure. It was postulated that almost all forms of
hypertension can be explained by impaired renal sodium
excretion [3, 4]. In more recent years, its critical role has
been established by the molecular identification of rare
mendelian disorders that cause high blood pressure [5]. The
fact that almost all monogenic forms of hypertension solved
to date are caused by altered renal sodium handling—
especially dysregulation of the aldosterone/mineralocorticoid
receptor (MR) cascade and its downstream targets [5]—
highlights the ability of this system to dominate long-term
blood pressure control in humans.
Habitual salt intake is closely related to blood pressure
levels. An epidemiologic study involving many centers
worldwide revealed that the systolic blood pressure slope
with age is correlated with dietary salt intake [6].
Experimental data in other terrestrial mammals have largely
confirmed the relationship between salt and blood pressure
[7], but it is also known that there is heterogeneity in salt
sensitivity of blood pressure. Indeed, blood pressure
response to high salt intake differs among individuals with
essential hypertension [8] ,a n dt h i sd i f f e r e n c ei ns a l t
sensitivity independently affects the outcome of cardiovas-
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MR in the kidneys plays a central role in the physiological
response to variations in dietary salt intake. In addition,
aldosterone, or activation of MR, is now recognized as an
important mediator of hypertension-associated target organ
damage. Hence, dysregulation of MR signaling not only
causes salt-dependent elevation of arterial pressure but also
can explain the increased cardiovascular morbidity and
mortality in patients with salt-sensitive hypertension.
Moreover, in an effort to identify the mechanism of salt-
induced organ damage, we have recently discovered
signaling cross-talk between MR and small GTPase Rac1,
challenging the prevailing view of the regulation of the
aldosterone/MR signaling cascade [10￿￿]. This article
reviews recent progress regarding MR function and
regulation, in order to address the role of MR signaling in
the pathogenesis of salt-sensitive hypertension.
Renal Salt Handling and Aldosterone/MR
One of the major roles of the kidneys is to control fluid
homeostasis in the body. About 99% of the filtered sodium
and water is reabsorbed in the tubules via a primary active
inward transport. Although the sodium handled in the distal
nephron is a minor portion of the sodium reabsorbed in the
kidneys, the fine tuning of sodium and water regulation
occurs in these segments. The aldosterone/MR cascade
exerts its effects in the so-called aldosterone-sensitive distal
nephron (ASDN), which includes the late distal convoluted
tubule, connecting tubule, and collecting duct. Upon
binding of aldosterone, MR undergoes conformational
changes, dissociation from chaperone proteins, dimeriza-
tion, and translocation to the nucleus, where it binds to the
responsive elements in the promoter regions of target genes
to regulate transcription. Among the aldosterone-induced
genes, serum/glucocorticoid regulated kinase 1 (SGK1)
plays a major role in the control of sodium reabsorption.
Studies have clarified the detailed mechanism of epithelial
sodium channel (ENaC) regulation by SGK1 (Fig. 1).
Nedd4-2 (neural precursor cell expressed, developmentally
downregulated 4-2) is a HECT domain–containing E3
ubiquitin ligase that interacts with the C terminus of ENaC
subunits and maintains the plasma membrane ENaC at low
levels through ubiquitination-dependent mechanisms.
Aldosterone-induced SGK1 phosphorylates the Nedd4-2,
which disrupts the tonic inhibition of ENaC by Nedd4-2,
leading to indirect stimulation of sodium transport. SGK1
phosphorylation of Nedd4-2 results in 14-3-3 binding and
suppresses Nedd4-2–ENaC interaction [11]. ENaC muta-
tions in Liddle’s syndrome also affect the Nedd4-2
interaction, leading to constitutive ENaC expression and
increased sodium reabsorption [12]. SGK1 may also
modulate ENaC activity though a mechanism independent
of Nedd4-2 [13].
In addition, SGK1 regulates ENaCα gene transcription
through epigenetic mechanism. A putative transcription
factor, AF9, interacts with Dot1a, a histone H3 Lys-79
methyltransferase, to form a nuclear repressor complex with
chromatin at specific regions of the ENaCα promoter,
where it regulates histone H3 Lys-79 methylation and
thereby represses ENaCα transcription under basal con-
ditions. SGK1 phosphorylates AF9 and impairs the Dot1a-
AF9 interaction, leading to histone hypomethylation and
de-repression of ENaCα transcription [14].
Glucocorticoid-induced leucine-zipper protein (GILZ)
was identified as an aldosterone-induced protein in cortical
collecting duct cell lines. Raf-MEK-ERK1/2 forms a
regulatory complex with ENaC and inhibits its function.
GILZ interacts with the ENaC regulatory complex and
augments ENaC activity via the inhibition of Raf-1 [15]. It
is also shown to inhibit Nedd4-2 through the recruitment of
SGK1 [16].
Recent studies also suggest that aldosterone/MR signal-
ing interacts with the WNK kinase family. Mutations in
WNK1 and WNK4 are known to be associated with
pseudohypoaldosteronism type II (PHAII), or Gordon’s
syndrome [17]. WNK4 has the SGK1 phosphorylation
sites, and the WNK4 mutant mimicking SGK1 phosphory-
lation shows altered effects on the sodium-chloride cotrans-
Fig. 1 Mechanism of epithelial sodium channel (ENaC) regulation by
the aldosterone/mineralocorticoid receptor (MR) system. Aldosterone-
induced SGK1 phosphorylates Nedd4-2, which disrupts the tonic
inhibition of ENaC. Glucocorticoid-induced leucine-zipper protein
(GILZ) augments ENaC activity through the recruitment of SGK1 to
ENaC complex including Nedd4-2, as well as through the inhibition of
Raf-1. In addition, SGK1 regulates ENaCα gene transcription through
phosphorylation of AF9, leading to the inhibition of Dot1a/AF9
interaction and the histone hypomethylation of ENaCα transcription.
Aldosterone/MR signaling also interacts with the WNK kinase family.
Nedd4-2—neural precursor cell expressed, developmentally downregulated
4-2; SGK1—serum/glucocorticoid regulated kinase 1
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potassium channel (ROMK), leading to speculation that
SGK1 and WNK4 act in concert to regulate the balance
between sodium reabsorption and potassium secretion [18,
19]. Conversely, some investigators have reported that
SGK1 activity is regulated by WNK family members
[20]. In addition, aldosterone can induce the expression of
kidney-specific WNK1, a kinase-deficient isoform that
lacks the N-terminal 437 residues of WNK1 [21]. These
results indicate that the aldosterone/MR system controls
electrolyte and fluid homeostasis in part through interaction
with WNK kinases. Some studies have shown that a
common single nucleotide polymorphism (SNP) in WNK
kinases show an association with altered blood pressure
[22], although its significance remains to be validated.
Role of MR Signaling in Target Organ Damage
Although abnormal activation of the renin-angiotensin-
aldosterone system has long been reported to participate
in the occurrence of end-organ damage in hypertensive
patients, many studies have focused on the role of
angiotensin II, and relatively little attention has been paid
to the role of aldosterone. However, two clinical studies, the
Randomized Aldactone Evaluation Study (RALES) and the
Eplerenone Post-Acute Myocardial Infarction Heart Failure
and Survival Study (EPHESUS), have demonstrated that
MR antagonists, added to standard therapy including
angiotensin-converting enzyme (ACE) inhibitor, substan-
tially improved cardiac mortality [23, 24]; subsequent
studies revealed that aldosterone/MR can have an effect
on the vasculature, inducing inflammation, oxidative stress,
fibrosis, and increased sympathetic tone. Hypertensive
kidney damage is an important cause of end-stage renal
disease. Accumulating data indicate that aldosterone/MR
signaling is also a key mediator of the kidney injury.
Although the precise mechanisms remain unclear, aldoste-
rone/MR is shown to possess deleterious effects on non-
ASDN cells in the kidneys, such as podocytes. Enhanced
MR effector mechanism is closely related to protein leakage
from the kidneys [25], a strong risk factor for progression
of chronic kidney disease. Clinical studies have also
revealed that MR blockade reduces urinary protein excre-
tion even better than ACE inhibition [26]. In addition,
experimental studies, including our own, have demonstrat-
ed the unequivocal benefits of a selective MR antagonist,
eplerenone, in ameliorating proteinuria and glomerular
podocyte damage [10￿￿, 27]. It has been postulated that
aldosterone/MR induces apoptosis or alters the adhesive
capacity of podocytes [28, 29]. Because these cells are
highly differentiated and are considered to lack proliferative
capacity, the reduced numbers of podocytes cause denuda-
tion of the glomerular basement membrane and adhesion to
Bowman’s capsule, a common pathway leading to glomerulo-
sclerosis. MR is known to be present in other kidney cells,
including mesangial cells and renal fibroblasts, and to
modulate their functions via profibrotic action or alteration of
cell cycle regulators [30]. In addition, aldosterone activates
NF-κB in principal cells of the cortical collecting duct
through mechanisms that involve SGK1 [31]. NF-κB
regulates inflammation and transepithelial sodium transport,
so this observation indicates a convergence of sodium
reabsorption and inflammatory stimulation in the collecting
duct. In line with these experimental data, subjects with
aldosterone overproduction have a high incidence of renal
dysfunction [32]. These cellular effects could be relevant to
kidney injury in hypertensive patients with increased aldo-
sterone/MR activity.
Aldosterone Excess and Salt-Sensitive Hypertension
Abnormal aldosterone production causes salt-sensitive
hypertension. Aldosterone is produced in the zona glomer-
ulosa, the outermost layer of adrenal cortex. Angiotensin II
and hyperkalemia promote conversion of cholesterol to
pregnenolone via stimulation of steroidogenic acute regu-
latory protein (StAR), and of corticosterone to aldosterone
via aldosterone synthase (CYP11B2). The layer-specific
synthesis is ensured by the specific expression of CYP11B2
and by the suppression of 17α hydroxylase (CYP17A1)
that is necessary for the production of cortisol and
androgen. Glucocorticoid-remediable aldosteronism, a
monogenic form of hypertension, results from fusion of
the synthetic portion of CYP11B2 and the regulator portion
of CYP11B1 that catalyzes the conversion of 11-
deoxycortisol to cortisol, leading to aldosterone production
in response to ACTH in zona fasciculata [33].
Aldosterone secretion is controlled by circadian rhythm,
anddisruptionofessential clockcomponentsisshownto cause
abnormal aldosterone synthesis. Doi et al. [34￿￿] reported that
mice lacking Cryptochrome-1 (Cry1) and Cryptochrome-2
(Cry2) show salt-sensitive hypertension because of abnor-
mally high synthesis of aldosterone. Further research revealed
that Hsd3b6, an enzyme that catalyzes the conversion
of Δ
5-3β-hydroxysteroids into hormonally active Δ
4-3-
ketosteroids, is exclusive expressed in mice in the zona
glomerulosa of the adrenal gland, and that this enzyme is
upregulated in Cry knockout mice, causing enhanced aldo-
sterone production [34￿￿]. They also showed that HSD3B1, a
human counterpart of mouse Hsd3b6, is enriched in human
zona glomerulosa cells, indicating a role for this enzyme in
the layer-specific biosynthesis of aldosterone. Future studies
will clarify the role of HSD3B1 in the dysregulation of
aldosterone and salt-sensitive hypertension in humans.
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(PA) is a common cause of blood pressure elevation. One
study reported that this disorder accounts for more than
10% of cases of hypertension [35]. In addition, patients
with PA exhibit cardiac remodeling, endothelial dysfunc-
tion, and albuminuria [32, 36], especially when salt intake
is not decreased. One of the classic animal models for PA is
a rat receiving chronic infusion of aldosterone and a high-
salt diet. Using this model, we have shown that albuminuria
induced by aldosterone and salt is attributable to podocyte
injury [37]. Another disorder that exhibits increased
aldosterone production is metabolic syndrome. Metabolic
syndrome, in which visceral obesity is clustered with
hypertension, impaired glucose tolerance, and dyslipidemia,
has become increasingly frequent in Western societies.
Obese hypertensive patients exhibit greater depressor
response to salt restriction than lean hypertensives, indicat-
ing increased salt sensitivity [38]. Several factors may
induce abnormal natriuresis in obesity-induced salt-
sensitive hypertension, but excessive aldosterone concen-
trations in plasma have been reported to be common in
obese patients [39].
Adipose tissue is now recognized as an endocrine
organ that secretes a variety of adipokines. Components
of the renin-angiotensin system are present in adipose
tissues and are increased in obese patients. In addition,
studies have demonstrated that adipocytes secrete as-yet-
undefined factors that stimulate aldosterone synthesis in
adrenal gland [40]. We have shown that serum aldosterone
levels were increased in obese, spontaneously hyperten-
sive rats (SHR), a rat model of metabolic syndrome, as
compared with those in nonobese SHR [27]. Moreover, the
aldosterone secretagogue activity of fat-cell–conditioned
medium derived from obese SHR was greater than that
from nonobese SHR. Metabolic syndrome is associated
with the increased risk of albuminuria [41]. In obese
SHR, there was an age-dependent increase in urinary
protein excretion accompanied by podocyte injury, where-
as no such findings were noted in nonobese SHR.
Moreover, administration of an MR blocker markedly
decreased the podocyte damage and proteinuria. Thus,
increased aldosterone excretion can also contribute to the
renal injury in metabolic syndrome.
Factors That Affect Aldosterone/MR Signaling
and Its Relevance to Salt-Sensitive Hypertension
Without doubt, aldosterone is the central regulator of MR-
mediated gene transcription, but it is not the sole determi-
nant of MR signaling activity. Indeed, recent studies have
led to a paradigm shift in our understanding of the
regulation of the aldosterone/MR cascade. MR belongs to
a superfamily of nuclear receptors, and the mechanisms that
regulate other nuclear receptors can largely be applied to
MR. Nuclear receptor signaling is modulated by several
factors, including the receptor expression levels (through
either altered transcription or stability), ligands, post-
translational modifications, interaction with other signaling
pathways, and recruitment of co-regulator molecules.
Studies have indicated that these mechanisms are also
involved in the regulation of MR activity [42, 43￿].
The human MR gene (NR3C2) is located at chromosome
4q31 and consists of 10 exons. NR3C2 has two different
promoters, termed P1 and P2, which generate alternative
transcription products. In addition, a variant that lacks the
hinge region and ligand binding domain of MR (hMRΔ5,6)
is shown to be present in humans [44]. This variant
possesses transcriptional activity in vitro, which is inde-
pendent of the ligand. The presence of these human MR
transcript variants may be involved in the context-dependent
modulation of MR expression. In support of this idea, Krug et
al. [43￿] recently reported that MR expression is increased in
aorta from aged rats, which causes enhanced MR signaling
and age-associated cardiovascular damage. Aging is one of
the important factors that modulate sodium excretion
capacity, and the same mechanism may be applicable to
age-related salt-sensitive hypertension.
Glucocorticoid can also act as a ligand for MR. Endoge-
nous glucocorticoids—cortisol in humans and corticosterone
in rodents—manifest the same affinity for MR as aldosterone
in vitro, and the cortisol concentration is approximately 1,000
times higher than the concentration of aldosterone. In the
kidneys, the ligand selectivity for MR is at least in part
explained by the presence of 11β-hydroxysteroid dehydroge-
nase type 2 (11βHSD2), which converts cortisol to inactive
cortisone. Mutation or inactivation of this enzyme leads to
glucocorticoid-induced MR activation and hypertension [5].
In contrast, MR is considered to be occupied by glucocorti-
coids in cardiomyocytes. Nonetheless, their agonistic activity
is considered to be least potent in vivo, and the artificial
overexpression of 11βHSD2 in the heart causes cardiac
hypertrophy due to aldosterone-induced MR activation.
Therefore, cortisol can prevent aldosterone binding and
MR activation in physiologic conditions. However, it is
postulated that the ability of cortisol to activate MR is
influenced by the intracellular redox state, with increased
oxidative stress resulting in cortisol-induced MR activation
[45].
Small GTPase Rac1, a member of the Rho family
GTPases, regulates diverse biologic processes, including
cell migration, cell cycle, activation of NADPH oxidase,
and cell adhesion [46]. In addition, recent evidence
suggests that Rac1 serves as a key regulator of nuclear
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MR and Rac1 was shown to be an alternative pathway that
potentiates MR activity, both in vitro and in vivo [10￿￿]. In
an in vitro study assessing nuclear trafficking using green
fluorescent protein (GFP)–tagged MR, transfection of
active Rac1 could induce nuclear translocation of MR-
GFP even in the absence of aldosterone, and it further
increased nuclear accumulation in the presence of aldoste-
rone. In a luciferase reporter assay, overexpression of active
Rac1 significantly potentiated aldosterone-induced MR
transcriptional activity. This effect was not observed in
other Rho GTPases, including RhoA and Cdc42. Rac1
induced MR activation even without aldosterone, but when
aldosterone was added, the level of transcriptional activity
was 20 times higher, suggesting that aldosterone increases
Rac1-stimulated MR activation. In vitro experiments using
cultured podocytes have had identical findings.
Rho GDP dissociation inhibitor (RhoGDI) is a negative
regulator of Rho GTPases. In mice lacking the alpha
subtype of RhoGDI (RhoGDIαKO), no morphologic
abnormality of the kidneys was noted at E18.5, indicating
that the nephrogenesis is normal. However, the knockout
mice exhibited severe proteinuria and glomerulosclerosis
t h a tp r o g r e s s e dw i t ha g e[ 10￿￿]. Electron microscopy
revealed extensive foot process effacement, suggesting that
severe proteinuria in this model could be attributable to
podocyte damage. Rac1 activity was found to be upregu-
lated exclusively in the kidneys, whereas RhoA activity
was not. Consistent with this finding, renal injury in
RhoGDIαKO mice was inhibited by the administration of
a Rac-specific inhibitor, but Rho-kinase inhibitor had no
protective effect. In this model, nuclear MR protein in the
kidneys, as well as its downstream mediator Sgk1, was
upregulated despite comparable serum aldosterone levels in
RhoGDIαKO mice and their wild-type littermates. More-
over, inhibition of Rac1 activity antagonized the increased
MR signaling, indicating an interaction between Rac1 and
MR in vivo. In support of this idea, an MR blocker
markedly reduced the nephrotic-range proteinuria and
histologic change in the glomeruli of the RhoGDIαKO
mice. In sum, we conclude that the crosstalk between Rac1
and MR activity is a novel mechanism that potentiates MR
activity.
Aldosterone/MR signaling is closely related to dietary
salt intake. Excessive salt intake can cause MR activation
through an unidentified mechanism [48], leading to the
unfavorable synergistic action of aldosterone and high salt
intake. In relation to this unresolved mystery, we have
obtained evidence suggesting that Rac1 plays a key role in
salt-induced MR activation and hypertension. The Dahl rat
is a well-established model of salt-sensitive hypertension
and glomerular injury. In this model, the MR downstream
mediator SGK1 is paradoxically elevated in response to
high sodium loading [49] despite appropriate suppression
of plasma aldosterone, an observation implicated in the
pathogenesis of salt-dependent elevation of blood pressure.
The role of salt-induced MR activation in this model is
further supported by the protective effects of eplerenone
[27]. In our experiments, we have found that renal Rac1
was also activated by a high-salt diet in Dahl salt-sensitive
rats [10￿￿], and that Rac1 inhibitor considerably attenuated
hypertension and glomerular damage, along with the SGK1
repression. Thus, changes in Rac1 activity, as well as in
plasma aldosterone concentrations, can modulate MR
activation, and the Rac1 activity can be modulated by
sodium status, causing inappropriate MR activity in a
subpopulation of subjects with salt-sensitive hypertension.
We consider that these two mechanisms can be interdepen-
dent. Our preliminary experiments revealed that an inhibitor
of the Rho/Rho-kinase pathway had no depressor effects in
our model, in contrast to the effect of Rac1 blockade. Of
note, however, a recent study revealed that angiotensin II
enhances the Rho-kinase pathway through the regulation of
the Rho guanine exchange factor Arhgef1, which is
responsible for angiotensin II-dependent, salt-independent
hypertension through vasoconstriction [50]. Taking these
observations together, it is interesting to speculate that
vascular Rho/Rho-kinase plays a role in angiotensin II-
dependent hypertension via vasoconstriction, whereas renal
Rac1 is involved in salt-sensitive hypertension through
MR-mediated sodium retention.
Conclusions
Accumulating studies reveal that aldosterone/MR plays a
significant role in the development of salt-sensitive hyper-
tension and associated end-organ damage. In addition,
recent data indicate that besides systemic aldosterone, MR
signaling activity is regulated locally and can be involved
in the pathogenesis of salt-sensitive hypertension. For
terrestrial tetrapods, the aldosterone/MR system is the
principal regulatory mechanism maintaining water and
electrolyte homeostasis necessary for the independent
existence on land. The multiple regulatory system of
aldosterone/MR axis may have served primarily to ensure
efficient sodium and water homeostasis in a low-salt
environment. Excessive salt intake in modern industrialized
societies results in inappropriate suppression of the aldo-
sterone/MR axis, causing hypertension, cardiovascular
damage, and kidney dysfunction. Future studies will clarify
the detailed mechanism for the interdependent regulation of
salt homeostasis and the aldosterone/MR system, and its
relevance in salt-sensitive hypertension.
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